High-dose intravenous immunoglobulin may be an efficient treatment option for patients with late-onset high-grade immune effector cell-associated hematotoxicity refractory to standard therapies.
作者信息
Laham Yousef, Ringelstein-Harlev Shimrit, Kurnik Daniel, Fineman Riva, Yehudai-Ofir Dana, Bonstein Lilach, Setter-Marco Noga, Braun Eyal, Ghersin Itai, Zuckerman Tsila, Beyar-Katz Ofrat
机构信息
Department of Internal Medicine H, Rambam Health Care Campus, Haifa.
Department of Hematology and Bone Marrow Transplantation, Rambam Health Care Campus, Haifa.
出版信息
Haematologica. 2025 May 1;110(5):1232-1235. doi: 10.3324/haematol.2024.286714. Epub 2025 Jan 9.
Abstract
摘要
Zotero 插件